A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung D
Principal Investigator
Study Number
STUDY02001417
Summary
The purpose of this study is to learn about the effects of a study medicine, Epetraborole, to assess the efficacy for treating refractory MAC, to see how safe Epetraborole is for patients with refractory MAC, to confirm the dosage, to understand how Epetraborole leaves your body, and to assess how you feel while taking the study drug.
Phase
II/III
Contact
Available at the following location(s)
- Lebanon
View more details at ClinicalTrials.gov
Do you need help with some of the labels on this page?
Read our glossary of terms